Part Ⅹ of database building: tag and structure of the adjuvant therapy of colorectal cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WANG Xiaodong ¹ , ZENG Yu ^1,2 ,  LI Li ¹

1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Medicine, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

LI Li, Email: drlili116@126.com

Keywords：

colorectal cancer; database; big data; adjuvant therapy; tag; structure

DOI：

10.7507/1007-9424.202106113

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explain details of the adjuvant therapy of colorectal cancer in detail as well as their tags and structures of Database from Colorectal Cancer (DACCA) in the West China Hospital.Method The article was described in words.Results The details of the adjuvant therapy of colorectal cancer included adjuvant treatment therapies, the necessity of adjuvant intravenous chemotherapy, the acceptance of adjuvant chemotherapy, the number of courses of adjuvant chemotherapy, the toxicity of adjuvant chemotherapy, the evaluation of curative effect after adjuvant chemotherapy, the standardized degree of adjuvant chemotherapy, targeted therapy, the necessity of adjuvant radiotherapy, the availability of specialty physicians recommending adjuvant radiotherapy to patients with colorectal cancer, the acceptance of adjuvant radiotherapy, radiotherapy related adverse reactions, and effect evaluation after adjuvant radiotherapy of the DACCA in the West China Hospital were defined. The data labels corresponding to each item in the database and the structured ways needed for the big data application stage in detail were explained. And the error correction notes for all classification items were described.Conclusions Through the detailed description of the details of the adjuvant therapy of colorectal cancer of DACCA in West China Hospital, it provides the standard and basis for the clinical application of DACCA in the future, and provides reference for other peers who wish to build a colorectal cancer database.

Citation： WANG Xiaodong, ZENG Yu, LI Li. Part Ⅹ of database building: tag and structure of the adjuvant therapy of colorectal cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(8): 1070-1077. doi: 10.7507/1007-9424.202106113 Copy

1.	汪晓东, 林容若, 刘健博, 等. 数据库建设第七部分: 结直肠癌手术特征的标签与结构化(二). 中国普外基础与临床杂志, 2020, 27(10): 1295-1300.
2.	汪晓东, 林容若, 刘健博, 等. 数据库建设第七部分: 结直肠癌手术特征的标签与结构化(一). 中国普外基础与临床杂志, 2020, 27(9): 1150-1152.
3.	CSCO 临床数据委员会. CSCO database. https://www.sinyoo.net/csco/. 2015.
4.	博识医疗云公司数据库. https://www.boshicloud.com/. 2014.
5.	明智医疗公司数据库. http://www.wiseltd.cn/. 2015.
6.	中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020 年版). 中华外科杂志, 2020, 58(8): 561-585.
7.	Iwamoto S, Maeda H, Hazama S, et al. Efficacy of CapeOX plus cetuximab treatment as a first-line therapy for patients with extended RAS/BRAF/PIK3CA wild-type advanced or metastatic colorectal cancer. J Cancer, 2018, 9(22): 4092-4098.
8.	Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase Ⅲ, noninferiority trial. Ann Oncol, 2018, 29(3): 624-631.
9.	刘勇, 汪晓东, 朱佳怡, 等. 数据库研究第十部分: 结直肠癌的辅助治疗特征分析. 中国普外基础与临床杂志, 2021, 28(7): 937-944.
10.	Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase Ⅱa trial. J Nutr, 2019, 149(7): 1133-1139.
11.	Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 2004, 22(2): 229-237.
12.	Hwang J, Marshall JL. Targeted therapy for colorectal cancer. Curr Opin Investig Drugs, 2006, 7(12): 1062-1066.
13.	Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw, 2009, 7(8): 838-881.

1. 汪晓东, 林容若, 刘健博, 等. 数据库建设第七部分: 结直肠癌手术特征的标签与结构化(二). 中国普外基础与临床杂志, 2020, 27(10): 1295-1300.
2. 汪晓东, 林容若, 刘健博, 等. 数据库建设第七部分: 结直肠癌手术特征的标签与结构化(一). 中国普外基础与临床杂志, 2020, 27(9): 1150-1152.
3. CSCO 临床数据委员会. CSCO database. https://www.sinyoo.net/csco/. 2015.
4. 博识医疗云公司数据库. https://www.boshicloud.com/. 2014.
5. 明智医疗公司数据库. http://www.wiseltd.cn/. 2015.
6. 中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020 年版). 中华外科杂志, 2020, 58(8): 561-585.
7. Iwamoto S, Maeda H, Hazama S, et al. Efficacy of CapeOX plus cetuximab treatment as a first-line therapy for patients with extended RAS/BRAF/PIK3CA wild-type advanced or metastatic colorectal cancer. J Cancer, 2018, 9(22): 4092-4098.
8. Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase Ⅲ, noninferiority trial. Ann Oncol, 2018, 29(3): 624-631.
9. 刘勇, 汪晓东, 朱佳怡, 等. 数据库研究第十部分: 结直肠癌的辅助治疗特征分析. 中国普外基础与临床杂志, 2021, 28(7): 937-944.
10. Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase Ⅱa trial. J Nutr, 2019, 149(7): 1133-1139.
11. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 2004, 22(2): 229-237.
12. Hwang J, Marshall JL. Targeted therapy for colorectal cancer. Curr Opin Investig Drugs, 2006, 7(12): 1062-1066.
13. Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw, 2009, 7(8): 838-881.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Part Ⅹ of database building: tag and structure of the adjuvant therapy of colorectal cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content